Search the Newsreel

(URGN) Volatility Zones as Tactical Triggers

This article from Stock Traders Daily discusses Urogen Pharma Ltd. (NASDAQ: URGN) and presents AI-generated trading strategies based on volatility zones. It highlights strong sentiment across all time horizons supporting an overweight bias, notes the absence of resistance levels above the current price, and …

UroGen Pharma (URGN): TD Bank group discloses 3.37M shares, 6.9% beneficial stake

The Toronto-Dominion Bank and TD Securities Inc. have jointly reported beneficial ownership of 3,371,263 ordinary shares of UroGen Pharma Ltd. This represents a 6.9% stake in the company. The filing specifies the individual voting and dispositive powers of both TD Bank and TD Securities …

UroGen (URGN) Q2 2026 Earnings Call Transcript

UroGen Pharma (URGN) reported strong Q2 2026 results driven by the ZUSDURI launch, with total revenue reaching $72.5 million. ZUSDURI's commercial demand is expanding into community urology practices, showing increased repeat utilization and physician confidence. The company is advancing its pipeline with NDA submissions …

Urogen Pharma (NASDAQ:URGN) Hits New 1-Year High - Time to Buy?

Urogen Pharma (NASDAQ:URGN) recently reached a new 52-week high of $48.21, reflecting generally positive analyst sentiment with a "Moderate Buy" consensus rating and price targets up to $75. Despite exceeding revenue expectations with $72.46 million, the company missed EPS estimates, reporting a loss of …

URGN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that UroGen Pharma Ltd. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit!

Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against UroGen Pharma Ltd. (NASDAQ:URGN) on behalf of investors who purchased securities between July 27, 2023, and May 15, 2025. The lawsuit alleges that UroGen made misleading statements and failed to disclose critical …

UroGen Pharma (URGN) Is Up 21.7% After Q2 Revenue Triples And Loss Narrows Has The Bull Case Changed?

UroGen Pharma (URGN) reported significantly improved Q2 2026 results, with revenue tripling to US$72.46 million and net loss narrowing to US$14.35 million. These results indicate emerging operating leverage, supported by an expanded loan facility, which provides financial flexibility despite the company remaining unprofitable. While …

UroGen Pharma (URGN) Stock Looks Fairly Priced Despite Its 210% Run

UroGen Pharma (URGN) has seen a significant 210% return over the last five years, but its current valuation suggests the stock is now fairly priced rather than undervalued. The company's P/S ratio is aligned with its modelled fair P/S, indicating no clear discount or …

Q3 EPS Estimates for Urogen Pharma Lifted by HC Wainwright

HC Wainwright has raised its Q3 2026 EPS estimate for Urogen Pharma to a loss of $0.07 per share from a previous loss of $0.37, while maintaining a "Buy" rating and a $75 price target. This positive adjustment comes as Urogen Pharma’s Q2 revenue …

UroGen Pharma Ltd. Revenue Breakdown – MUN:UR8

UroGen Pharma Ltd. (MUN:UR8) generated €93.49 million in revenue last year, primarily from its RTGel Reverse Thermal Hydrogel segment, which accounted for €93.48 million. The majority of this revenue, €93.48 million, originated from Israel and the United States. This represents an increase from the …

Why UroGen Pharma (URGN) Is Up 22.8% After Q2 2026 Revenue Nearly Tripled And Losses Narrowed

UroGen Pharma (URGN) saw its stock rise 22.8% after reporting a nearly tripling of Q2 2026 revenue to US$72.46 million and a significant narrowing of its net loss to US$14.35 million. While the company's improved operating leverage supports its growth thesis, concerns remain regarding …

UroGen Pharma (URGN) Earnings Put Its Fair Value Debate Back In Focus

UroGen Pharma (URGN) reported strong Q2 2026 results, with increased sales and a reduced net loss, leading to significant stock price appreciation. This has sparked debate over its fair value, with one narrative suggesting it's 30% overvalued at $36.11, while another Discounted Cash Flow …

Urogen Pharma $URGN Shares Purchased by Hennion & Walsh Asset Management Inc.

Bullish: Analysts Just Made An Incredible Upgrade To Their UroGen Pharma Ltd. (NASDAQ:URGN) Forecasts

Analysts have significantly upgraded their forecasts for UroGen Pharma Ltd. (NASDAQ:URGN), increasing revenue estimates to $322 million for 2026 and sharply reducing the anticipated loss per share to $0.14. This positive revision reflects a projected 191% annualized revenue growth, much faster than the industry …

A Quick Look at Today's Ratings for UroGen Pharma Ltd(URGN.US), With a Forecast Between $48 to $75

This article provides an overview of recent analyst ratings for UroGen Pharma Ltd (URGN.US), highlighting a consensus among six analysts with a price target range of $48 to $75. The analysis suggests a potential upside of over 100% based on the current share price, …

UroGen Pharma Ltd. (URGN) Stock Price, News, Quote & History

This Yahoo Finance page provides a comprehensive overview of UroGen Pharma Ltd. (URGN) stock, including its real-time price, market performance, and company profile. It details key financial metrics, earnings trends, analyst ratings, and product pipeline, highlighting its focus on urothelial and specialty cancers.

TD Cowen Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Raises Target Price to $60

TD Cowen has reiterated its Buy rating for UroGen Pharma Ltd (URGN.US) and increased its price target to $60. This reflects a positive outlook from the firm regarding the company's financial prospects and market performance.

UroGen Pharma (URGN) Stock Jumps As Revenue Surge Outruns Loss Concerns

UroGen Pharma 2Q Loss $14.4M >URGN

UroGen Pharma reported a second-quarter net loss of $14.4 million. This financial update, released by the company, indicates its performance for the specified period.

Urogen Pharma (NASDAQ:URGN) Stock Price Up 9.1% - Here's Why

Urogen Pharma stock hits 52-week high at 43.97 USD

Urogen Pharma's stock has reached a new 52-week high of $43.97, reflecting a significant 116.89% increase over the past year. This surge is supported by positive analyst ratings, an increased price target from Oppenheimer for its Jelmyto product, and regulatory clearance for its UGN-501 …

URGN Stock Jumps As Street Hikes Targets On Patent Wins

UroGen Pharma (URGN) stock surged over 15% following multiple analyst target hikes and news of significant patent wins. Oppenheimer, Goldman Sachs, and Guggenheim raised their price targets, citing strong sales forecasts for Zusduri, early launch traction, and a new patent extending protection until 2044. …

Earnings call transcript: UroGen Pharma tops Q2 2026 revenue forecast

UroGen Pharma reported strong Q2 2026 revenue of $72.5 million, significantly exceeding forecasts, driven by the successful launch of its bladder-cancer drug ZUSDURI. The company's net loss narrowed to $14.4 million, and shares climbed 11.9% in premarket trading. Management increased full-year operating expense guidance …

UroGen Pharma Q2 Net Loss Narrows, Revenue Rises

UroGen Pharma reported a narrowed net loss of $28.3 million for Q2, down from $37.4 million in the prior year, while revenue increased to $16.7 million from $12.3 million. The company's lead product, Jelmyto, saw increased sales. UroGen Pharma also announced a recent private …

Urogen Pharma (URGN) Reports Q2 Loss, Tops Revenue Estimates

Urogen Pharma (URGN) reported a Q2 loss of $0.28 per share, outperforming the Zacks Consensus Estimate of a $0.38 loss, and revenues of $72.46 million, exceeding estimates by 16.42%. The company's shares have risen 70.5% year-to-date, and it currently holds a Zacks Rank #2 …

Urogen Pharma Ltd reports results for the quarter ended June 30 - Earnings Summary

Urogen Pharma Ltd has released its earnings summary for the quarter that ended on June 30. The article, sourced from Reuters, provides a brief overview of the company's financial performance during this period. Readers can access the full report via TradingView.

UroGen Q2 revenue jumps to $72.5 million on ZUSDURI launch

UroGen Pharma (URGN) reported a significant increase in Q2 2026 revenue, reaching $72.5 million, largely due to the successful commercial launch of ZUSDURI, which contributed $50.4 million. Despite a net loss of $14.4 million, the company's financial position remains stable with $108.0 million in …

Q3 2025 Urogen Pharma Ltd Earnings Call Transcript

UroGen Pharma Ltd (URGN) reported strong preliminary demand revenue for October 2025, significantly increasing over the prior three months, and has secured broad insurance coverage for its products. The company is expanding its sales force and is on track for an NDA submission for …

UroGen Reports $50.4 Million of ZUSDURI Revenue and Provides Second Quarter 2026 Financial Results and Highlights

UroGen Pharma Ltd. announced strong financial results for Q2 2026, with ZUSDURI generating $50.4 million in revenue, a 73% quarter-over-quarter increase, and reported a significant new U.S. patent allowance extending protection for ZUSDURI and UGN-103 into July 2044. The company is advancing its pipeline, …

Urogen Pharma (NASDAQ:URGN) Announces Quarterly Earnings Results, Misses Estimates By $0.02 EPS

UroGen Pharma earnings beat, revenue topped estimates

Price-Driven Insight from (URGN) for Rule-Based Strategy

This article from Stock Traders Daily provides a price-driven insight for Urogen Pharma Ltd. (NASDAQ: URGN), highlighting weak near-term sentiment but strong mid- to long-term outlook. It details specific institutional trading strategies (Long, Breakout, Short) with entry, target, and stop-loss levels, alongside a multi-timeframe …

UroGen Pharma Market Sentiment

This article provides an overview of market sentiment for UroGen Pharma (URGN), including analyst consensus, short interest, options flow, and insider activity. Key signals show a "Buy" analyst consensus, declining short interest, and more calls than puts, indicating a bullish sentiment, although insider activity …

Enterprise value to revenue forward of UroGen Pharma Ltd. – NASDAQ:URGN

This article presents financial data for UroGen Pharma Ltd. (NASDAQ: URGN), specifically its enterprise value to revenue forward. It notes that the market is currently closed with no trades recorded. The information is provided by TradingView, sourcing market data from ICE Data Services and …